长期伊马替尼导致慢性肾间质病变、缺血性肾损伤伴微血管病变1例
A Case of Chronic Renal Interstitial Lesions and Ischemic Renal Injury with Microvascular Lesions Induced by Long-Term Imatinib Use
DOI: 10.12677/acm.2025.153637, PDF,   
作者: 廖 进, 龙李熳, 陈 莹, 殷 薇, 向梦琴：湖南省人民医院(湖南师范大学附属第一医院)肾脏内科，湖南 长沙；刘抗寒*：湖南省人民医院(湖南师范大学附属第一医院)肾脏内科，湖南 长沙；湖南省慢性肾脏病诊疗中心，湖南 长沙
关键词: 伊马替尼；肾间质病变；缺血性肾损伤；微血管病变；Imatinib； Renal Interstitial Lesions； Ischemic Renal Injury； Microvascular Lesions
摘要: 伊马替尼是第一代络氨酸激酶抑制剂(TKI)，在治疗费城染色体阳性的慢性髓性白血病(Ph + CML)和不能切除和/或发生转移的恶性胃肠道间质瘤(GIST)的成人患者中取得了巨大成功。由于伊马替尼的肾脏清除可以忽略，对于肾功能损害的患者不需要调整剂量，一般认为肾毒性较小。然而，伊马替尼导致的肾脏损伤逐步受到重视。现报道一例长期服用伊马替尼导致慢性肾间质病变、缺血性肾损伤伴微血管病变的患者。
Abstract: Imatinib, a first-generation tyrosine kinase inhibitor (TKI), has achieved significant success in treating Philadelphia chromosome-positive chronic myeloid leukemia (Ph + CML) and unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) in adult patients. Since renal clearance of imatinib is negligible, dose adjustment is not required for patients with renal impairment, and it is generally considered to have low nephrotoxicity. However, renal injury caused by imatinib is gradually gaining attention. This report presents a case of chronic renal interstitial lesions and ischemic renal injury with microvascular lesions induced by long-term imatinib use.
文章引用：廖进, 龙李熳, 陈莹, 殷薇, 向梦琴, 刘抗寒. 长期伊马替尼导致慢性肾间质病变、缺血性肾损伤伴微血管病变1例[J]. 临床医学进展, 2025, 15(3): 460-465. https://doi.org/10.12677/acm.2025.153637

参考文献

[1] Foringer, J.R., Verani, R.R., Tjia, V.M., Finkel, K.W., Samuels, J.A. and Guntupalli, J.S. (2005) Acute Renal Failure Secondary to Imatinib Mesylate Treatment in Prostate Cancer. Annals of Pharmacotherapy, 39, 2136-2138. [Google Scholar] [CrossRef] [PubMed]
[2] Gafter-Gvili, A., Ram, R., Gafter, U., Shpilberg, O. and Raanani, P. (2010) Renal Failure Associated with Tyrosine Kinase Inhibitors—Case Report and Review of the Literature. Leukemia Research, 34, 123-127. [Google Scholar] [CrossRef] [PubMed]
[3] Barta, V.S., Uppal, N.N., Pullman, J.M., Levy, A.T. and Jhaveri, K.D. (2017) Acute Tubular Injury Associated with Imatinib (Gleevec): A Case Report and Review of the Literature. Journal of Onco-Nephrology, 1, 57-61. [Google Scholar] [CrossRef] 
[4] Agrawal, R., Saha, K. and Mohapatra, S. (2016) A Rare Case of Imatinib Mesylate Induced Acute Kidney Injury. International Journal of Basic and Clinical Pharmacology, 16, 1678-1680. [Google Scholar] [CrossRef] 
[5] Zarrabi, K., Sweeny, K. and Keresztes, R. (2016) Imatinib Mesylate-Induced Kidney Injury in the Treatment of a Gastrointestinal Stromal Tumor. Case Reports in Internal Medicine, 4, 30-34. [Google Scholar] [CrossRef] 
[6] Vidal-Petiot, E., Rea, D., Serrano, F., Stehlé, T., Gardin, C., Rousselot, P., et al. (2016) Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia, 16, 169-174. [Google Scholar] [CrossRef] [PubMed]
[7] Marcolino, M.S., Boersma, E., Clementino, N.C.D., Macedo, A.V., Marx-Neto, A.D., Silva, M.H.C.R., et al. (2011) Imatinib Treatment Duration Is Related to Decreased Estimated Glomerular Filtration Rate in Chronic Myeloid Leukemia Patients. Annals of Oncology, 22, 2073-2079. [Google Scholar] [CrossRef] [PubMed]
[8] Singh, A.K., Hussain, S., Ahmed, R., Agrawal, N., Bhurani, D., Klugar, M., et al. (2022) Impact of Imatinib Treatment on Renal Function in Chronic Myeloid Leukaemia Patients. Nephrology, 27, 318-326. [Google Scholar] [CrossRef] [PubMed]
[9] Sakurai, M., Kikuchi, T., Karigane, D., Kasahara, H., Matsuki, E., Hashida, R., et al. (2019) Renal Dysfunction and Anemia Associated with Long-Term Imatinib Treatment in Patients with Chronic Myelogenous Leukemia. International Journal of Hematology, 109, 292-298. [Google Scholar] [CrossRef] [PubMed]
[10] Seki, Y., Nagano, O., Koda, R., Morita, S. and Hasegawa, G. (2020) Pathological Findings Suggesting Vascular Endothelial Damage in Multiple Organs in Chronic Myelogenous Leukemia Patients on Long-Term Tyrosine Kinase Inhibitor Therapy. International Journal of Hematology, 112, 584-591. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, G., Zhuo, N., Luo, Y. and Li, J. (2021) Imatinib-Induced Podocytopathies in a Patient with Gastrointestinal Stromal Tumor. Renal Failure, 43, 886-889. [Google Scholar] [CrossRef] [PubMed]
[12] Morita, N., Ozaki, T., Yokota, S., Sasaki, H., Watanabe, M., Takahashi, K., et al. (2021) Focal Segmental Glomerulosclerosis and Concurrent Glomerular Microangiopathy after Long-Term Imatinib Administration. CEN Case Reports, 11, 134-140. [Google Scholar] [CrossRef] [PubMed]

为你推荐